# A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

> **NCT05111509** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Yusuf Menda** · enrollment: 20 (estimated)

## Conditions studied

- Neuroendocrine Tumor Grade 2
- Neuroendocrine Tumor Grade 1

## Interventions

- **DRUG:** [203Pb]VMT-α-NET
- **DEVICE:** SPECT/CT

## Key facts

- **NCT ID:** NCT05111509
- **Lead sponsor:** Yusuf Menda
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-22
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05111509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05111509, "A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05111509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*